Hong Kong stock biopharma followed two trends today: Innovent Biologics rose over 3.5%, with PD-1 innovative drugs having staged catalysts, performing relatively steadily among Hong Kong-listed innovative drug stocks; AliHealth edged up 0.2%, with medical e-commerce almost flat. On the other hand, Xuanzhu Biopharma fell over 6%, as its clinical-stage pipeline needs time to validate, and capital lacks patience; Summit Therapeutics also saw a significant drop, with clinical small-cap stocks carrying relatively high risks 😔
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
